Please assess the completion status of the following clinical trial:

Trial Title: JKB-121 for the Treatment of Nonalcoholic Steatohepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Provision of written informed consent~3. Biopsy-proven NASH within 12 months or at screening~4. ALT \> 40 U/L for women and \> 60 U/L for men at screening and at least once in the previous 12 months.~5. HBA1C of ≤ 9.0~Exclusion Criteria:~1. Any chronic liver disease other than NASH~2. Cirrhosis, as assessed clinically or histologically~3. Presence of vascular liver disease~4. BMI ≤ 25 kg/m2~5. Excessive alcohol use (\> 20 g/day) within the past 2 years~6. AST or ALT \> 250 U/L.~7. Type 1 diabetes mellitus~8. Bariatric surgery in the past 5 years.~9. Weight gain of \> 5% in past 6 months or \> 10% change in past 12 months.~10. Contraindication to MRI~11. Inadequate venous access~12. HIV antibody positive, hepatitis B surface antigen positive (HBsAg), or Hepatitis C virus (HCV) RNA positive.~13. Receiving an elemental diet or parenteral nutrition~14. Chronic pancreatitis or pancreatic insufficiency~15. Any history of complications of cirrhosis~16. Concurrent conditions:~    * Inflammatory bowel disease~   * Significant cardiac disease~   * chronic infection or immune mediated disease~   * Any malignant disease~   * Prior solid organ transplant~   * Any other concurrent condition which, in the opinion of the investigator, could impact adversely on the subject participating or the interpretation of the study data.~17. Concurrent medications which may treat NASH~18. HbA1C \> 9.0%~19. Pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): JKB 121, 5 mg twice daily
- B (Type: ACTIVE_COMPARATOR): JKB 121, 10 mg twice daily
- C (Type: PLACEBO_COMPARATOR): Identical appearing placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).